Inovio Pharma (INO), GeneOne Initiate Patient Recruitment for MERS Vaccine Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Stocks and yen struggle as tech troubles weigh
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen hits fresh 34-year lows against dollar ahead of BOJ meeting
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Inovio (INO) Bullish Stance Reiterated at Maxim Group Amid MERS Trial Patient Recruitment and Zika Vaccine Progress
January 28, 2016 11:18 AM ESTMaxim Group analyst Jason McCarthy reiterated his Buy rating and $14 price target on Inovio Pharmaceuticals (NASDAQ: INO) as MERS vaccine trial initiates patient recruitment and amid progress on a vaccine targeting the Zika Virus.
The analyst highlighted:
Inovio and partner GeneOne Life Science (KSE:011000-NR) announced that the phase I study of GLS-5300 (vaccine targeting MERS, Middle East Respiratory... More
